Advertisement

Expert Point of View: Caroline Robert, MD, PhD


Advertisement
Get Permission

Caroline Robert, MD, PhD

Caroline Robert, MD, PhD

The paper’s invited discussant, Caroline Robert, MD, PhD, of the Institut de Cancérologie Gustave Roussy, Villejuif, France, said OpACIN-neo attained its goal of reducing toxicity and maintaining efficacy. The regimen of two courses of ipilimumab (Yervoy) at 1 mg/kg plus nivolumab (Opdivo) at 3 mg/kg maintained high clinical responses and decreased grade 3 to 4 toxicity from 90% to 20%, she said.

Dr. Robert agreed that a neoadjuvant immunotherapy approach is rational in melanoma, pointing out that it has been shown in animal models to increase tumor-specific CD8-positive T cells. “We know we are in a period of paradigm-shifting, including in this context in place of surgery,” she said. The achievement of a pathologic response, in several other cancer types, has predicted for relapses but not overall survival. “In this study, the follow-up is too short to know if pathologic responses will predict for better survival,” she said. “We look forward to seeing if it does…. The long-term benefit of pathologic complete response remains to be proven.” 

DISCLOSURE: Dr. Robert has served as a consultant to Roche, Novartis, Bristol-Myers Squibb, MSD, Pierre Fabré, Array and Effector.


Related Articles

Neoadjuvant Therapy With Reduced-Dose Immunotherapy for Stage III Melanoma

In patients with stage III melanoma, a reduced-dose neoadjuvant immunotherapy combination was well tolerated and led to high pathologic response rates, in the phase II OpACIN-neo trial presented at the European Society for Medical Oncology (ESMO) 2018 Congress.1

“Neoadjuvant ipilimumab (Yervoy) at ...

Advertisement

Advertisement



Advertisement